Revvity's Valuation Puzzle: Is the Life Sciences Giant a Bargain or Overpriced?
Revvity shares have faced significant pressure, down over 13% in the past year. A deep dive into its valuation reveals a stark contradiction: while a cash flow model suggests the stock is undervalued, its price-to-earnings multiple tells a different story. We examine the numbers and what they mean for investors.